본문 바로가기
KERD
논문KCI 등재

Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study

백용한|이세준|박효진|이동기|이관식|문병수|전재윤|이상인|안상훈|문영명|송건훈|김명환|한광협
연세대학교의과대학 (Yonsei University College of Medicine)|2005.06|Yonsei Medical Journal|제46권 제3호|pp. 399-407

1

조회

0

다운로드

3

인용

0

참고문헌

키워드

lactuloseHepatic encephalopathyliver cirrhosisrifaximin
주제분류의학일반

초록

Rifaximin has been reported to be effective for the treatment of hepatic encephalopathy (HE) in Europe. However, it is unknown whether Rifaximin is effective for the treatment of HE in Koreans, therefore we conducted a open-label prospective randomized study to evaluate the efficacy of rifaximin versus lactulose in Korean patients. Fifty-four patients with liver cirrhosis and hepatic encephalopathy were enrolled. Thirty-two patients were randomized to receive rifaximin and 22 to receive lactulose both over a 7-day periods. Before and at the end of treatment, gradation of blood ammonia, flapping tremor, mental status, number connection test (NCT) were performed and estimation of HE indexes determined. Both rifaximin and lactulose were effective in the majority of patients (84.4% and 95.4%, respectively, p=0.315). Blood NH3, flapping tremor, mental status, and NCT was significantly improved by rifaximin and lactulose, and the post- treatment levels of these measures were similar for the rifaximin and lactulose-treated groups, as was the HE index (rifaximin group (10.0→4.2, p=0.000); lactulose group (11.3→5.0, p=0.000)). One patient treated with rifaximin complained of abdominal pain, which was easily controlled. There was no episode of renal function impairment in either treatment group. Rifaximin proved to be as safe and as effective as lactulose for the treatment of Korean patients with hepatic encephalopathy.

Abstract

Rifaximin has been reported to be effective for the treatment of hepatic encephalopathy (HE) in Europe. However, it is unknown whether Rifaximin is effective for the treatment of HE in Koreans, therefore we conducted a open-label prospective randomized study to evaluate the efficacy of rifaximin versus lactulose in Korean patients. Fifty-four patients with liver cirrhosis and hepatic encephalopathy were enrolled. Thirty-two patients were randomized to receive rifaximin and 22 to receive lactulose both over a 7-day periods. Before and at the end of treatment, gradation of blood ammonia, flapping tremor, mental status, number connection test (NCT) were performed and estimation of HE indexes determined. Both rifaximin and lactulose were effective in the majority of patients (84.4% and 95.4%, respectively, p=0.315). Blood NH3, flapping tremor, mental status, and NCT was significantly improved by rifaximin and lactulose, and the post- treatment levels of these measures were similar for the rifaximin and lactulose-treated groups, as was the HE index (rifaximin group (10.0→4.2, p=0.000); lactulose group (11.3→5.0, p=0.000)). One patient treated with rifaximin complained of abdominal pain, which was easily controlled. There was no episode of renal function impairment in either treatment group. Rifaximin proved to be as safe and as effective as lactulose for the treatment of Korean patients with hepatic encephalopathy.

참고문헌 (33)

  1. "Hepatic encephalopathy: a review.", 2, pp.122~30 (2003)
  2. "Treatment of hepatic encephalopathy", 337, pp.473~9 (1997)
  3. "the treatment of major complications of cirrhosis", pp.639~57
  4. "disaccharides and colonic flora. Clinical consequences", 53, pp.930~42 (1997)
  5. "Lactulose and combination therapy of hepatic encephalopathy the role of the intestinal microflora", 14(1), pp.53~63 (1996)
  6. "Rifaximin A review of its antibacterial activity pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria", 49, pp.467~84 (1995)
  7. "A non-absorbable rifamycin for treatment of hepatic encephalopathy", pp.387~92
  8. "Rifaximine versus neomycin in the treatment of portosystemic encephalopathy", pp.403~7
  9. "Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics", pp.175~8
  10. "Treatment of hepatic encephalopathy with non-absorbable antibiotics", pp.14~6
  11. "double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy", pp.109~18
  12. "Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.", 13, pp.593~601 (1997)
  13. "Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study", 12, pp.203~8 (2000)
  14. "Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial", 38, pp.51~8 (2003)
  15. "Racial differences in responses to therapy with interferon in chronic hepatitis C Consensus Interferon Study Group.", 30, pp.787~93 (1999)
  16. "Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis", 2, pp.820~4 (2004)
  17. "Effect of race on outcome of orthotopic liver transplantation a cohort study", 359, pp.287~93 (2002)
  18. "Prevalence of viral hepatitis markers in Korean patients with hepatocellular carcinoma", 13, pp.306~10 (1998)
  19. "Epidemiology of alcoholic liver disease", 24, pp.217~32 (2004)
  20. "Small bowel bacterial overgrowth in patients with alcoholic cirrhosis", 40, pp.1252~6 (1995)
  21. "Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy", pp.573~83
  22. "The relation of the trail making test to organic brain damage", pp.393~4
  23. "Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy", pp.541~50
  24. "Control of chronic portal-systemic encephalopathy by lactulose"
  25. "A controlled clinical trial of lactulose in hepatic encephalopathy", pp.827~32
  26. "Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy", 26, pp.1410~4 (1997)
  27. "Non-absorbable disaccharides for hepatic encephalopathy systematic review of randomised trials", 328, pp.1046~51 (2004)
  28. "Management of hepatic encephalopathy", 17(3), pp.260~7 (2002)
  29. "Hypernatremia in hepatic failure", pp.1257~60
  30. "Metronidazole pharmacokinetics in patients with hepatic encephalopathy", pp.117~23
  31. "Pharmacokinetic study of rifaximin after oral administration in healthy volunteers", pp.51~6
  32. "Hepatic encephalopathy-Definition, nomenclature, diagnosis, and quantification: Final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998", 35(menclature sis), pp.716~21 (2002)
  33. "Challenges of designing hepatic encephalopathy treatment trials", 38, pp.527~8 (2003)

이 간행물의 다른 논문 (14건)

Efficacy of Oral Etidronate for Skeletal Disease in JapanTsuyoshi Takeda, Yoshihiro Sato, Jun Iwamotopp. 313-320Interest group influence over drug pricing policy reform in South Korea김한중, 정우진pp. 321-330Development of a Structural Model Explaining Medication Compliance of Persons with Schizophrenia민성길, 서미아pp. 331-340Limited Effect of CpG ODN in Preventing Type 1 Diabetes in NOD Mice조현철, 정춘희, 김미진, 심명숙, 신영구, 이병준, 박은섭, 김문규, 김수기pp. 341-346Effectiveness of Real-time Quantitative PCR Compare to Repeat (REP-)PCR for the Diagnosis of Charcot-Marie-Tooth Type 1A and Hereditary Neuropathy with Liability to Pressure Palsies최종락, 임종백, 선우일남, 이은경, 이창훈, 이운형pp. 347-352
원문 보기